Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study

Kerstin Jurk; Korbinian F Rothenaicher; Kathrin Groß; Heidi Rossmann; Gerhard Weißer; Irene Schmidtmann; Thomas Münzel; Christine Espinola-Klein

doi:10.3389/fcvm.2022.865166

Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study

Front Cardiovasc Med. 2022 May 6:9:865166. doi: 10.3389/fcvm.2022.865166. eCollection 2022.

Authors

Kerstin Jurk¹, Korbinian F Rothenaicher², Kathrin Groß¹, Heidi Rossmann³, Gerhard Weißer², Irene Schmidtmann⁴, Thomas Münzel^{1

5}, Christine Espinola-Klein^{1

2}

Affiliations

¹ Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany.
² Center for Cardiology, Cardiology III-Angiology, University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany.
³ Institute for Clinical and Laboratory Medicine, University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany.
⁴ Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany.
⁵ Center for Cardiology, Cardiology I-General and Interventional Cardiology and Intensive Care, University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany.

Abstract

Patients with peripheral arterial disease (PAD) benefit from combination therapy with acetylsalicylic acid (ASA, 100 mg, one time per day) plus low-dose rivaroxaban (2.5 mg, two times per day) compared to ASA monotherapy. In particular, major adverse cardiac and limb events were significantly reduced after peripheral endovascular revascularization (EVR). In this pilot study, the platelet activation status in vivo and platelet reactivity in vitro were longitudinally analyzed by flow cytometric assays and calibrated automated thrombography in platelet-rich plasma (PRP) from 10 patients with PAD receiving ASA (100 mg, one time per day) before EVR, ASA plus clopidogrel (75 mg, one time per day) after EVR, and ASA plus rivaroxaban (2.5 mg, two times per day) during a long-term follow-up. Platelet responsiveness to clopidogrel was compared to additional 10 patients with stable PAD and clopidogrel (75 mg, one time per day) monotherapy. ASA plus rivaroxaban treatment resulted in a significantly decreased thrombin peak in PRP for two triggers, namely, low concentration of tissue factor (TF) and thrombin, compared to ASA monotherapy. TF-controlled thrombin generation was additionally characterized by a significantly prolonged lag time in PRP and platelet-free plasma during ASA plus rivaroxaban combination therapy. In comparison, ASA plus clopidogrel treatment presented a significant reduction of the thrombin peak in PRP, which was less pronounced than during subsequent ASA plus rivaroxaban therapy. Platelet responsiveness to clopidogrel was observed for 60% of patients receiving ASA plus clopidogrel and clopidogrel monotherapy, respectively. Blocking of CD36 on the platelet surface further reduced the thrombin peak in PRP induced by TF for all three therapy regimes. Platelet activation in vivo and in response to the GPVI-agonist convulxin or thrombin in vitro was similar, whereas integrin αIIbβ3 activation and α-granule release induced by the PAR-1 activating peptide TRAP-6 were significantly diminished during ASA plus rivaroxaban treatment compared to ASA monotherapy. In conclusion, the data of this pilot study indicate an inhibitory effect of rivaroxaban on the thrombin propagation phase of CD36-sensitive platelet thrombin formation in patients with PAD treated with ASA plus rivaroxaban combination therapy, which is associated with decreased PAR-1 but not thrombin-mediated platelet activation.

Keywords: acetylsalicylic acid; clopidogrel; peripheral arterial disease; platelets; rivaroxaban.